SAN DIEGO, CA—(Marketwired – June 23, 2015) – MyDx, Inc. (OTCQB: MYDX), creator of MyDxâ„¢ (My Diagnostic), the first handheld chemical analyzer for consumers, has elected four new independent directors: Edward Roffman, Federico Pier, George A. Jackoboice and Michael J. Harris.
The board of directors now includes:
Daniel Yazbeck, Chairman & CEO – Daniel Yazbeck is a leading science, business and technology professional with nearly 15 years of experience guiding a variety of Fortune 500 companies. He has worked with Pfizer Pharmaceuticals as a Scientist specializing in chemical R&D technologies, as well as Panasonic, spearheading their new market, business and strategic product development activities in the Consumer Electronics Healthcare field. Daniel holds a Master's Degree in Medicinal Chemistry from McGill University with a minor in business, and is an investor and author of several world patents and research publications.
Thomas Gruber, Chief Financial Officer, Chief Operations Officer, Director and Secretary – Thomas has over 20 years of financial and senior executive management experience from publicly traded high–technology companies including Western Digital, I/O Magic, and nStor Technologies, Inc. Mr. Gruber received a Bachelor's of Business Administration degree from Ohio University and a Master of Business Administration degree from Pepperdine University. He also earned a CPA certification.
Dr. Steven M. Katz, Director– Dr. Steven Katz is the founder and owner of the Bronx Veterinary Center, the largest full service veterinary hospital in the Bronx, NY, which he founded in 1994, and is currently serving in his second term as New York State Assemblyman, 94th District. Dr. Katz obtained his BS degree from Cornell University and his Doctor of Veterinary Medicine from the University of Pennsylvania.
Edward Roffman, Director – Edward has over forty years of experience in accounting and finance, serving as a management consultant since April 2006 and as a principal of Creekside, LLC, a consulting firm. Edward co–founded LERNA, LLC and serves as the company's Chief Financial Officer. Mr. Roffman is a Certified Public Accountant and earned a Bachelor's of Business Administration from Temple University. Mr. Roffman has served on the Board of Directors and Audit Committees of Andalay Solar, Inc. and XRPro Sciences, Inc.
Federico Pier, Director – Federico has more than 20 years of experience in the commercial and private banking sectors, currently as Managing Director of Abacus Asset Management, and previously with Oppenheimer and Company, Bear Stearns and Prudential Securities. Mr. Pier received a Bachelor's degree from the University of North Texas and a Master's of Business Administration from the Graduate School of Management at the University of Dallas.
George A. Jackoboice, Jr., Director – George has over 20 years of senior management and investment experience, managing a portfolio of manufacturing, medical device, real estate and technology investments with Monarch Holdings, Inc. He is the co–founder of Bridge Street Capital Partners and serves on the investment committee. George earned a Bachelor's of Art degree from Denison University and a Master's of Business Administration from Harvard Business School.
Michael J. Harris, Director– Michael has more than 35 years of experience in various management positions with both domestic and international companies including President of Dyson Kistner Corporation and President and Chief Executive Officer of Thetford Corporation. Mike has served on the Board of Directors for the Recreational Vehicle Industry Association, Lighthouse for the Blind, the Mid–Hudson Civic Center and the Dutchess County Arts Council. He is currently Secretary/Treasurer of the Millman Harris Romano Foundation, Poughkeepsie, New York. Mike attended New York State University at New Paltz, New York.
Full complete Company information and bios for all Directors please visit the Company's website at https://www.cdxlife.com/.
“We are following best practices to achieve world class corporate governance and are delighted to announce our new Board members who will help guide MyDx while overseeing our audit, compensation, ethics, and nomination committees,” said Daniel Yazbeck, Chairman & CEO of MyDx, Inc. “With our successful funding and appointment of a highly qualified management team and board, in conjunction with our patented technology and first over advantage, we are have now set the stage for MyDx's rapid growth as we prepare to bring the first handheld chemical analyzer for consumers to market in 2015.”
About MyDx, Inc.
MyDx, Inc. (OTCQB: MYDX) is a science and technology company based in San Diego, California whose mission is to help people trust & verify what they put into their minds and bodies by revealing the chemicals in what they eat, drink and inhale. The Company has developed MyDxâ„¢, a portable analyzer that provides real–time chemical analysis and fits in the palm of your hands. MyDx leverages over a decade of established electronic nose technology to measure chemicals of interest and has four sensors being developed in its lab that are compatible with the MyDxâ„¢ App. For more information, please visit www.cdxlife.com.
Safe Harbor
This news release contains “forward–looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward–looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward–looking statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward–looking statements. These forward–looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov.